StockNews.com Begins Coverage on Marinus Pharmaceuticals (NASDAQ:MRNS)

Investment analysts at StockNews.com initiated coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a research report issued to clients and investors on Sunday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Several other research analysts also recently issued reports on MRNS. Royal Bank of Canada dropped their target price on shares of Marinus Pharmaceuticals from $3.00 to $1.00 and set a “sector perform” rating on the stock in a research note on Friday, October 25th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $4.00 price objective on shares of Marinus Pharmaceuticals in a research report on Thursday, November 14th. EF Hutton Acquisition Co. I raised Marinus Pharmaceuticals to a “strong-buy” rating in a report on Monday, September 30th. Truist Financial downgraded Marinus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, October 24th. Finally, HC Wainwright reiterated a “neutral” rating and issued a $2.00 price objective on shares of Marinus Pharmaceuticals in a report on Thursday, November 14th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, two have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $4.79.

Marinus Pharmaceuticals Price Performance

MRNS opened at $0.53 on Friday. The firm has a market cap of $29.45 million, a PE ratio of -0.22 and a beta of 1.03. The stock has a 50-day moving average price of $0.33 and a 200-day moving average price of $1.04. Marinus Pharmaceuticals has a 1 year low of $0.22 and a 1 year high of $11.26.

Hedge Funds Weigh In On Marinus Pharmaceuticals

Several institutional investors have recently made changes to their positions in MRNS. abrdn plc lifted its position in Marinus Pharmaceuticals by 146.1% during the third quarter. abrdn plc now owns 2,658,527 shares of the biopharmaceutical company’s stock valued at $4,679,000 after purchasing an additional 1,578,329 shares in the last quarter. Suvretta Capital Management LLC lifted its position in shares of Marinus Pharmaceuticals by 32.8% during the 3rd quarter. Suvretta Capital Management LLC now owns 5,073,913 shares of the biopharmaceutical company’s stock valued at $8,930,000 after buying an additional 1,253,901 shares in the last quarter. Franklin Resources Inc. lifted its position in shares of Marinus Pharmaceuticals by 34.9% during the 3rd quarter. Franklin Resources Inc. now owns 4,713,014 shares of the biopharmaceutical company’s stock valued at $8,483,000 after buying an additional 1,219,871 shares in the last quarter. GSA Capital Partners LLP grew its stake in shares of Marinus Pharmaceuticals by 409.4% during the 3rd quarter. GSA Capital Partners LLP now owns 1,016,634 shares of the biopharmaceutical company’s stock valued at $1,789,000 after acquiring an additional 817,050 shares during the period. Finally, Acadian Asset Management LLC purchased a new stake in Marinus Pharmaceuticals in the 2nd quarter worth approximately $813,000. Institutional investors own 98.80% of the company’s stock.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.